These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21170263)

  • 1. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.
    Bera S; Greiner S; Choudhury A; Dispenzieri A; Spitz DR; Russell SJ; Goel A
    Neoplasia; 2010 Dec; 12(12):980-92. PubMed ID: 21170263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
    Salem K; Brown CO; Schibler J; Goel A
    Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
    Goel A; Dispenzieri A; Geyer SM; Greiner S; Peng KW; Russell SJ
    Blood; 2006 May; 107(10):4063-70. PubMed ID: 16424391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase.
    Brown CO; Salem K; Wagner BA; Bera S; Singh N; Tiwari A; Choudhury A; Buettner GR; Goel A
    Biochem J; 2012 Jun; 444(3):515-27. PubMed ID: 22471522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
    Grigorieva I; Thomas X; Epstein J
    Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.
    Wallace SR; Oken MM; Lunetta KL; Panoskaltsis-Mortari A; Masellis AM
    Cancer; 2001 Apr; 91(7):1219-30. PubMed ID: 11283920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased longevity of hematopoiesis in continuous marrow cultures and radiation resistance of marrow stromal and hematopoietic progenitor cells from caspase-1 homozygous recombinant-negative (knockout) mice.
    Epperly M; Berhane H; Cao S; Shields D; Franicola D; Goff JP; Zhang X; Wang H; Friedlander R; Greenberger JS
    In Vivo; 2013; 27(4):419-30. PubMed ID: 23812211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the bifunctional sulfoxide MMS350, a radiation mitigator, on hematopoiesis in long-term bone marrow cultures and on radioresistance of marrow stromal cell lines.
    Shinde A; Epperly MW; Cao S; Franicola D; Shields D; Wang H; Wipf P; Sprachman MM; Greenberger JS
    In Vivo; 2014; 28(4):457-65. PubMed ID: 24982210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells.
    Schibler J; Tomanek-Chalkley AM; Reedy JL; Zhan F; Spitz DR; Schultz MK; Goel A
    PLoS One; 2016; 11(11):e0167323. PubMed ID: 27902770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioresistance of bone marrow stromal and hematopoietic progenitor cell lines derived from Nrf2-/- homozygous deletion recombinant-negative mice.
    Berhane H; Epperly MW; Cao S; Goff JP; Franicola D; Wang H; Greenberger JS
    In Vivo; 2013; 27(5):571-82. PubMed ID: 23988890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
    Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
    Lust JA; Lacy MQ; Zeldenrust SR; Dispenzieri A; Gertz MA; Witzig TE; Kumar S; Hayman SR; Russell SJ; Buadi FK; Geyer SM; Campbell ME; Kyle RA; Rajkumar SV; Greipp PR; Kline MP; Xiong Y; Moon-Tasson LL; Donovan KA
    Mayo Clin Proc; 2009 Feb; 84(2):114-22. PubMed ID: 19181644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
    Voorhees PM; Chen Q; Small GW; Kuhn DJ; Hunsucker SA; Nemeth JA; Orlowski RZ
    Br J Haematol; 2009 May; 145(4):481-90. PubMed ID: 19344406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.
    Hönemann D; Chatterjee M; Savino R; Bommert K; Burger R; Gramatzki M; Dörken B; Bargou RC
    Int J Cancer; 2001 Sep; 93(5):674-80. PubMed ID: 11477577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells.
    Smith MR; Xie T; Joshi I; Schilder RJ
    Br J Haematol; 1998 Sep; 102(4):1090-7. PubMed ID: 9734662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enforced expression of superoxide dismutase 2/manganese superoxide dismutase disrupts autocrine interleukin-6 stimulation in human multiple myeloma cells and enhances dexamethasone-induced apoptosis.
    Hodge DR; Xiao W; Peng B; Cherry JC; Munroe DJ; Farrar WL
    Cancer Res; 2005 Jul; 65(14):6255-63. PubMed ID: 16024627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.